What is Wenxin Keli?

Identity and evidence
Wenxin Keli is discussed as a multi-ingredient Chinese herbal formula. Its name, traditional context, research record, product identity, and regulatory status answer different questions and should not be treated as interchangeable.

Names and identity #
Research papers use names including Wenxin Keli, Wenxin Granule, and the abbreviation WXKL. A shared name does not by itself prove that two products have the same ingredients, manufacturing controls, labeling, or legal status.

What this page does not claim #
This page does not claim that Wenxin Keli is approved, authorized, or marketed as a medicine in the reader’s jurisdiction. A peer-reviewed paper repeating a regulatory statement is not a substitute for a current primary regulatory record.



Formula described in the literature #
A 1,200-participant randomized trial described the studied preparation as containing five main components:

Codonopsis
Panax notoginseng
Nardostachys
amber
Polygonatum rhizome

Botanical naming varies across papers, and this list describes the preparation reported by that source. Verify the full label of the exact product instead of assuming that every item sold under the name Wenxin Keli matches a research preparation.
Review the ingredient guide and its source boundaries.


Traditional context and modern outcomes #
Traditional Chinese medicine descriptions use a different conceptual framework from biomedical research. Traditional terminology can document how a formula is described or used within that system, but it does not prove a modern clinical outcome.
NCCIH notes that studies of Chinese herbal products have had mixed results and that poor study quality often prevents firm conclusions. Traditional context, laboratory findings, animal findings, and human clinical results should therefore remain in separate, clearly labeled sections.


What human research has studied #
One multicenter randomized, double-blind, placebo-controlled trial studied a specific Wenxin Keli preparation for four weeks in 1,200 participants in China with frequent premature ventricular contractions. That study population, preparation, duration, and measured outcomes define what the trial can address; they do not establish results for every arrhythmia, every product, or long-term use.
An overview of eight systematic reviews concerning atrial fibrillation found that most assessed outcomes had low or very low certainty. Risk of bias, publication bias, small samples, and weaknesses in the underlying trials reduced confidence in the reported findings.
See research organized by study type and limitation.


Safety and practical limits #
“Natural” does not mean risk-free. Herbal products can cause adverse effects, interact with medicines, differ from their labels, or contain contaminants. A short clinical trial may not detect uncommon or long-term harms.
Do not replace or delay prescribed treatment or medical assessment based on this page. Discuss the exact product label with a doctor or pharmacist, especially when taking medicines or other supplements, managing a health condition, pregnant or nursing, or considering use for a child.
Read the safety questions or review the FAQ.



Sources #

Randomized, double-blind, placebo-controlled multicenter trial in frequent premature ventricular contractions
Overview of systematic reviews on Wenxin Keli for atrial fibrillation
National Center for Complementary and Integrative Health: Traditional Chinese Medicine

Last evidence review: August 20, 2026. Source inclusion documents the evidence and its limits; it is not an endorsement or treatment recommendation.